

2025

- Abeyakoon, C., Wellard, C., Chung, E., Hodgson, D., Rodin, D., Prica, A.,...Kuruville, J. (2025). *Survival Outcomes In Nodal Peripheral T-Cell Lymphoma Following Primary And Second-Line Treatment: An Australasian-Canadian Collaborative Study* 2025 18th International Conference on Malignant Lymphoma, Lugano, Switzerland. https://doi.org/10.1002/hon.70096_761
- Alem, A. Z., Mohanty, I., Pati, N., Wellard, C., Chung, E., Hawkes, E. A.,...Niyonsenga, T. (2025). Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning Approaches. *Journal of Clinical Medicine*, 14(20). <https://doi.org/10.3390/jcm14207445>
- Aoki, N., Moore, E., Wellard, C., Ashrafi, E., Zhang, T., Min, C.,...Spencer, A. (2025). Regional trends in first-line myeloma treatment: Real world results from the Australian & New Zealand and Asia-Pacific Myeloma and Related Diseases Registries 2025 Blood Annual Scientific Meeting, Perth, Australia.
- Aydin, G., Zhang, X., Petrie, D., Van der Walt, A., Reddel, S., Buzzard, K.,...Fanning, L. (2026). Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios. *Patient*, 19(3), 435-448. <https://doi.org/10.1007/s40271-025-00796-w>
- Carrillo de Albornoz, S., Zhang, X., Arnolda, R., MacPhail, A., Irving, A., Higgins, A. M.,...Petrie, D. (2025). Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia. *Blood Adv*, 9(20), 5367-5377. <https://doi.org/10.1182/bloodadvances.2025015867>
- Chung, E., Wang, L., Wellard, C., Barraclough, A., Campbell, B. A., Chong, G.,...Hawkes, E. A. (2025). Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study. *Haematologica* <https://doi.org/10.3324/haematol.2025.287919>
- Flint, A. W. J., Poole, A., Raasveld, S. J., Bailey, M., Brady, K., Chen, P. Y.,...McQuilten, Z. K. (2025). Blood Transfusion Practices in Intensive Care: A Prospective Observational Binational Study. *Crit Care Explor*, 7(3), e1197. <https://doi.org/10.1097/CCE.0000000000001197>
- TREATT Trial Investigators (2025). Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. *Lancet Haematol*, 12(1), e14-e22. [https://doi.org/10.1016/S2352-3026\(24\)00317-X](https://doi.org/10.1016/S2352-3026(24)00317-X)
- Irving, A., Petrie, D., Harris, A., Fanning, L., Wood, E. M., Moore, E.,...McQuilten, Z. (2025). A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data. *Pharmacoeconomics*, 44, 83–95. <https://doi.org/10.1007/s40273-025-01554-4>

- Kurucz, V. C., Flint, A. W. J., Poole, A., Reuland, M. C., van den Oord, C., Schaap, C. M.,...Group, I. S. (2025). Global transfusion practices in septic patients in the intensive care unit: insights from the InPUT-study sub-analysis. *Transfusion*. <https://doi.org/10.1111/trf.18445>
- L, L. S., Wellard, C., Rajagopal, R., Harrison, S. J., Khot, A., Quach, H.,...Spencer, A. (2025). No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry [Research Letter]. *Br J Haematol*, 208(1), 333-336. <https://doi.org/10.1111/bjh.70238>
- Li, J., Melsew, Y., Wellard, C., Moore, E. M., Ho, P. J., Quach, H.,...Spencer, A. (2025). New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts – A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR). *Clin Lymphoma Myeloma Leuk*. <https://doi.org/10.1016/j.clml.2025.10.013>
- Lim, K. J. C., Wellard, C., Moore, E., Ninkovic, S., Chng, W. J., Spencer, A.,...Quach, H. (2025). Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients. *Clin Lymphoma Myeloma Leuk*, 25(4), 243-248. <https://doi.org/10.1016/j.clml.2024.11.002>
- Loh, J. B., Wellard, C., Haysom, H. E., Sparrow, R. L., Wood, E. M., & McQuilten, Z. K. (2025). Outcomes of massive transfusion recipients administered ABO-incompatible fresh frozen plasma. *Transfusion*, 65(1), 58-72. <https://doi.org/10.1111/trf.18070>
- Loh, J. B., Wellard, C., Haysom, H. E., Sparrow, R. L., Wood, E. M., & McQuilten, Z. K. (2025). Outcomes of massive transfusion recipients administered ABO-incompatible fresh frozen plasma. *Transfusion*, 65(1), 58 - 72. <https://doi.org/10.1111/trf.18070>
- Martynchyk, A., Wellard, C., Chung, E., Bhopal, S. K., McQuilten, Z. K., Mulligan, S. P.,...Anderson, M. A. (2025). Characteristics of Australian and New Zealand patients with Chronic Lymphocytic Leukemia: a Lymphoma and Related Diseases Registry report. *Internal Medicine Journal*, 55(6), 937-943. <https://doi.org/10.1111/imj.70037>
- McQuilten, Z., O'Sullivan, M. V. N., Purcell, D., Edler, P., Meagher, N., Alcorn, K.,...Denholm, J. T. (2025). Convalescent plasma in hospitalised patients with COVID-19. *Intern Med J*. <https://doi.org/10.1111/imj.70253>
- Metcalf, R. A., Nahirniak, S., Guyatt, G., Bathla, A., White, S. K., Al-Riyami, A. Z.,...Stanworth, S. J. (2025). Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. *JAMA*, 334(7), 606-617. <https://doi.org/10.1001/jama.2025.7529>
- Mo, A., Wood, E., & McQuilten, Z. (2025). Platelet transfusion. *Curr Opin Hematol*, 32(1), 14-21. <https://doi.org/10.1097/MOH.0000000000000843>

- Mo, A., Wood, E. M., Shortt, J., & McQuilten, Z. K. (2025). Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes. *Transfusion*, 65(10), 1803-1809. <https://doi.org/10.1111/trf.18391>
- Nwokeocha, S., Haysom, H. E., Wellard, C., Roberts, T., Kachapila, M., Chee, M.,...Australian Haemoglobinopathy Registry (2025). Economic burden of sickle cell disease in Australia. *Intern Med J*, 55(8), 1251-1257. <https://doi.org/10.1111/imj.70092>
- Orman, Z., Reade, M. C., Marks, D. C., Howe, B. D., Bailey, M., Carrandi, A.,...Higgins, A. M. (2025). Cost-Effectiveness of Cryopreserved vs Liquid-Stored Platelets for Managing Surgical Bleeding. *JAMA Netw Open*, 8(12), e2554363. <https://doi.org/10.1001/jamanetworkopen.2025.54363>
- Reade, M. C., Marks, D. C., Howe, B. D., Bailey, M. J., Bannon, P. G., Eastwood, G. M.,...Cryopreserved vs Liquid Platelets II (CLIP-II) Investigators, t. A. a. N. Z. I. C. S. C. T. G., the Australian and New Zealand College of Anaesthetists Clinical Trials Network, and the Australasian Society of Cardiac and Thoracic Surgeons. (2025). Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial. *JAMA*. <https://doi.org/10.1001/jama.2025.23355>
- Schaap, C. M., Oomen, L. A., Raasveld, S. J., Schenk, J., de Bruin, S., Reuland, M. C.,...Group, I. S. (2025). Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unit. *Vox Sang*. <https://doi.org/10.1111/vox.70153>
- Sparrow, R. L., Haysom, H. E., Loh, J. B., Caithness, K., Mandapaka, K., Wellard, C.,...Wood, E. M. (2025). The Australian and New Zealand Massive Transfusion Registry: An innovation focusing on data collection, standardisation and interoperability between healthcare systems. *Health Inf Manag*, 18333583251375121. <https://doi.org/10.1177/18333583251375121>
- Thao, L. T. P., Buscher, H., Nguyen, T. L., Martucci, G., Gratz, J., Trummer, G.,...(ECMONet), I. E. N. (2025). Liberal or restrictive transfusion for veno-arterial extracorporeal membrane oxygenation patients: a target trial emulation using the OBLEX study data. *Crit Care*, 29(1), 360. <https://doi.org/10.1186/s13054-025-05606-1>
- van Haeren, M. M. T., Raasveld, S. J., de Bruin, S., Reuland, M. C., van den Oord, C., Schenk, J.,...Group, I. S. (2025). Plasma transfusion in the intensive care unit. *Transfusion*, 65(1), 73-87. <https://doi.org/10.1111/trf.18071>
- van Wonderen, S. F., Raasveld, S. J., Flint, A. W. J., Schenk, J., van den Oord, C., Reuland, M. C.,...Group, I. S. (2025). Platelet Transfusion Practices in the ICU: A Prospective Multicenter Cohort Study. *Crit Care Med*, 53(12), e2526-e2539. <https://doi.org/10.1097/CCM.0000000000006880>
- Wang, L., Chung, E., Wellard, C., Barraclough, A., Campbell, B. A., Chong, G.,...Hawkes, E. A. (2025). Definitions and use of tumour bulk in phase 3 lymphoma trials: a

comprehensive literature review. *Blood Advances*.
<https://doi.org/10.1182/bloodadvances.2024015072>

Wong, E. Y., Wellard, C., Ng, J. Y., Chung, E., McQuilten, Z. K., Opat, S.,...Taulikar, D. (2025). Real world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). *eJHaem*, 6(1). <https://doi.org/10.1002/jha2.1096>

Zhao, S., Wellard, C., Moore, E., Spencer, A., Quach, H., Ho, J. P.,...Rajagopal, R. (2025). Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCD: Results From the Australian and New Zealand Myeloma and Related Diseases Registry. *Clin Lymphoma Myeloma Leuk.*, 26(1), 49-56.
<https://doi.org/10.10162025.08.004./j.clml>

2024

Aoki, N., Chen, P. Y., Chen, W., Chng, W. J., Gan, G. G., Goh, Y. T.,...Investigators, A. M. (2024). The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR). *BMC Med Res Methodol*, 24(1), 102. <https://doi.org/10.1186/s12874-024-02227-0>

Aydin, G., Zhang, X., Petrie, D., Van der Walt, A., Reddel, S., Buzzard, K.,...Fanning, L. (2026). Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios. *Patient*, 19(3), 435-448. <https://doi.org/10.1007/s40271-025-00796-w>

Baggio, D., Chung, E., Wellard, C., Waters, N., Cushion, T., Chong, G.,...Opat, S. (2024). Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. *Intern Med J*, 54(7), 1223-1227. <https://doi.org/10.1111/imj.16445>

Barracough, A., Agrawal, S., Taulikar, D., Chong, G., Yoo, E., Cheah, C. Y.,...Hawkes, E. A. (2024). Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. *Haematologica*, 109(10).
<https://doi.org/10.3324/haematol.2023.284538>

Binkley, M. S., Flerlage, J. E., Savage, K. J., Akhtar, S., Steiner, R., Zhang, X.-Y.,...Kelly, K. M. (2024). International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. *Journal of Clinical Oncology*, JCO.23.01655.
<https://doi.org/10.1200/JCO.23.01655>

Buckstein, R., Callum, J., Prica, A., Bowen, D., Wells, R. A., Leber, B.,...Lin, Y. (2024). Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies. *Am J Hematol*, 99(3), 473-476. <https://doi.org/10.1002/ajh.27181>

- Caithness, K., Nair, J., Mohamed, M., Sridhar, S., Huang, Y., Mandapaka, K.,...Wood, E. (2025). First Tasmanian hospital joins the National Transfusion Dataset project: A case study with the Launceston General Hospital. 2025 BLOOD Annual Scientific Meeting, Perth, Australia.
- Carrillo de Albornoz, S., Chai, K. L., Higgins, A. M., Petrie, D., Wood, E. M., & McQuilten, Z. K. (2024). A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies. *Int J Technol Assess Health Care*, 40(1), e32.
<https://doi.org/10.1017/S026646232400028X>
- Carrillo de Albornoz, S., Higgins, A. M., Petrie, D., Irving, A., Fanning, L., Weinkove, R.,...McQuilten, Z. K. (2024). Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies. *Blood Adv*, 8(9), 2259-2267.
<https://doi.org/10.1182/bloodadvances.2023012047>
- Chai, K. L., Wellard, C., LTP, T., Aoki, N., Moore, E. M., Augustson, B. M.,...McQuilten, Z. K. (2024). Variation in immunoglobulin use and impact on survival in myeloma. *EJHaem*, 1 - 8. <https://doi.org/10.1002/jha2.938>
- Chai, K. L., Wellard, C., Thao, L., Aoki, N., Moore, E. M., Augustson, B. M.,...McQuilten, Z. K. (2024). Variation in immunoglobulin use and impact on survival in myeloma. *EJHaem*, 5(4), 690-697. <https://doi.org/10.1002/jha2.938>
- Chung, E. (2024). Comparing outcomes using registry versus clinician definitions of bulky disease in lymphoma care: An Australasian Lymphoma Registry (LaRDR) study. 2024 ACTA Clinical Trials and Registries Symposium, Melbourne (Australia).
- Chung, E., Wang, L., Wellard, C., Barraclough, A., Campbell, B., Chong, G.,...Hawkes, E. (2024a). *Distribution and Use of Bulky Disease in Lymphoma Care: A Study from the Australasian Lymphoma and Related Diseases Registry (LaRDR) 2024* European Hematology Association Congress, Madrid, Spain.
<https://doi.org/10.1002/hem3.104>
- Chung, E., Wang, L., Wellard, C., Barraclough, A., Campbell, B. A., Chong, G.,...Hawkes, E. A. (2024b). *Distribution and use of bulky disease in lymphoma care: A study from the Australasian Lymphoma and Related Diseases Registry (LaRDR) 2024* BLOOD Annual Scientific Meeting, Brisbane (Australia).
https://secure.tcc.co.nz/ei/images/BLOOD24/Blood_Supplement.pdf#page=302
- Dzik, S., Murphy, M., McQuilten, Z., & Callum, J. (2024). Recommended Papers of 2023 From the TMR Editorial Board. *Transfus Med Rev*, 38(1), 150808.
<https://doi.org/10.1016/j.tmr.2023.150808>
- Flint, A. W. J., Brady, K., Wood, E. M., Thao, L. T. P., Hammond, N., Knowles, S.,...George Institute for Global Health, t. A. a. N. Z. I. C. S. C. T. G. a. t. B. S. P. (2023). Transfusion practices in intensive care units: An Australian and New Zealand point prevalence study. *Crit Care Resusc*, 25(4), 193-200.
<https://doi.org/10.1016/j.ccrj.2023.10.006>

- Fox, L., Hunter, S., Ting, S., Thao, L. T. P., Heritier, S., Mills, A.,...Blombery, P. (2024). *Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia* 2024 American Society of Hematology Annual Meeting., San Diego, United States.
<https://ashpublications.org/blood/article/144/Supplement%201/1318/531733/Cellular-and-Cell-Free-Genomic-Characterization-of>
- Haysom, H., Wellard, C., Waters, N., Fox, V., Crichton, G., Henry, A.,...McQuilten, Z. (2024). Therapy and outcomes for anticipated NAIT pregnancies in the Australian Neonatal Alloimmune Thrombocytopenia (NAIT) Registry. 2024 BLOOD Annual Scientific Conference, Brisbane, Australia.
- Ho, P. J. M., E, Wellard, C., Quach, H., Blacklock, H., Harrison, S. J., MacDonald, E. J.,...Spencer, A. (2024). The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real-world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR). *BJHaem*, 205(4), 1337-1345.
<https://doi.org/10.1111/bjh.19624>
- Investigators, T. T. (2025). Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial. *Lancet Haematol*, 12(1), e14-e22. [https://doi.org/10.1016/S2352-3026\(24\)00317-X](https://doi.org/10.1016/S2352-3026(24)00317-X)
- Irving, A., Harris, A., Petrie, D., Avdic, D., Smith, J., Tran, L.,...Mcquilten, Z. K. (2024). Can clinical guidelines reduce variation in transfusion practise? A pre-post study of blood transfusions during cardiac arrest. *Vox Sanguinis*, 120(1), 47-54.
<https://doi.org/10.1111/vox.13751>
- Irving, A., Petrie, D., Harris, A., Fanning, L., Wood, E. M., Moore, E.,...McQuilten, Z. K. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. *PLoS One*, 19(8). <https://doi.org/10.1371/journal.pone.0308812>
- Lim, K. J. C., Wellard, C., Moore, E., Ninkovic, S., Chng, W. J., Spencer, A.,...Quach, H. (2025). Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients. *Clin Lymphoma Myeloma Leuk*, 25(4), 243-248. <https://doi.org/10.1016/j.clml.2024.11.002>
- Ling, J., Moore, E., Wellard, C., Spencer, A., & Sidiqi, M. (2025). Outcomes of patients with multiple myeloma post-BCMA directed treatment: an Australian perspective 2025 BLOOD Annual Scientific Meeting, Perth, Australia.
- Ling, V. W. T., Ashrafi, E., Wellard, C., Moore, E., Spencer, A., Tan, L. K.,...Chng, W. J. (2025). Improved Survival in Elderly Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. 2025 European Society for Blood Marrow Transplantation Annual Meeting, Florence, Italy.
- Maclean, M., Wellard, C., Ashrafi, E., Haysom, H. E., Sparrow, R. L., Wood, E. M., & McQuilten, Z. K. (2024). Ultra-Massive Transfusion: Predictors of Occurrence and

In-Hospital mortality From the Australian and New Zealand Massive Transfusion Registry (ANZ-MTR). *Transfus Med Rev*, 38(4), 150857.
<https://doi.org/10.1016/j.tmr.2024.150857>

MacPhail, A., Dendle, C., Slavin, M., & McQuilten, Z. (2024). Hospital-acquired bloodstream infections in patients with cancer: current knowledge and future directions. *J Hosp Infect*, 148, 39-50. <https://doi.org/10.1016/j.jhin.2024.03.002>

MacPhail, A., Dendle, C., Slavin, M., Weinkove, R., Bailey, M., Pilcher, D., & McQuilten, Z. (2024a). Neutropenic Sepsis in the Intensive Care Unit: Differences in Clinical Profile and Outcomes According to the Cause of Neutropenia. *Open Forum Infect Dis*, 11(6), ofae289. <https://doi.org/10.1093/ofid/ofae289>

MacPhail, A., Dendle, C., Slavin, M., Weinkove, R., Bailey, M., Pilcher, D., & McQuilten, Z. (2024). Neutropenic Sepsis in the Intensive Care Unit: Differences in Clinical Profile and Outcomes According to the Cause of Neutropenia. *Open Forum Infectious Diseases*, 11(6). <https://doi.org/10.1093/ofid/ofae289>

MacPhail, A., Dendle, C., Slavin, M., Weinkove, R., Bailey, M., Pilcher, D., & McQuilten, Z. (2024b). Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study. *Crit Care*, 28(1), 148. <https://doi.org/10.1186/s13054-024-04932-0>

Maurer, M., Parsons, S., Upshaw, J., Rodday, A., Friedberg, J., Gallamini, A.,...Evens, A. (2024). *Identification of Risk Categories and Stratification from the Advanced-Stage Hodgkin Lymphoma (AS-HL) International Prognostic Index (A-HIPI) Model* 2024 13th International Symposium on Hodgkin Lymphoma, Cologne, Germany. <https://www.hodgkinsymposium.org/abstracts-publications/737>

McQuilten, Z., Fox, L. C., Heritier, S., Fox, V., Young, L., Blombery, P.,...Wood, E. (2024). *Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial*. 2024 American Society of Hematology Annual Meeting, San Diego, United States.
<https://ashpublications.org/blood/article/144/Supplement%201/303/530330/Efficacy-and-Safety-of-Avatrombopag-in-Combination>

McQuilten, Z., Heritier, S., Fox, L., Fox, V., Young, L., Blombery, P.,...Wood, E. (2024). Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials. *BMJ Open*, 14. <https://doi.org/10.1136/bmjopen-2023-076246>

McQuilten, Z., van Tonder, T., Akers, C., Berry, C., Bielby, L., Brady, K.,...Wood, E. (2024). Building Australia's national transfusion data infrastructure: the National Transfusion Dataset (NTD) project. 2024 BLOOD Annual Scientific Meeting, Brisbane, Australia.

McQuilten, Z. K., Venkatesh, B., Jha, V., Roberts, J., Morpeth, S. C., Totterdell, J. A.,...Tong, S. Y. C. (2023). Anticoagulation Strategies in Non-Critically Ill Patients

with Covid-19. *NEJM Evid*, 2(2), EVIDoa2200293.

<https://doi.org/10.1056/EVIDoa2200293>

McQuilten, Z. K., Weinkove, R., Thao, L. T. P., Crispin, P., Degelia, A., Dendle, C.,...Wood, E. M. (2024). Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. *Blood Adv*, 8(7), 1787-1795. <https://doi.org/10.1182/bloodadvances.2023011231>

McQuilten, Z. K., Wood, E. M., & Medcalf, R. L. (2024). When to use tranexamic acid for the treatment of major bleeding? *J Thromb Haemost*, 22(3), 581-593.

<https://doi.org/10.1016/j.jtha.2023.10.001>

Minson, A., Hamad, N., Di Ciaccio, P., Talaulikar, D., Ku, M., Ratnasingam, S.,...Dickinson, M. (2024). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. *Br J Haematol*, 204(2), 548-554.

<https://doi.org/10.1111/bjh.19179>

Mitra, B., Essery, M., Somesh, A., Talarico, C., Olaussen, A., Anderson, D., & Meadley, B. (2024). Agreement of point-of-care and laboratory lactate levels among trauma patients and association with transfusion. *Vox Sanguinis*, 120(2), 188-192.

<https://doi.org/10.1111/vox.13770>

Mitra, B., Talarico, C. S., Olaussen, A., Anderson, D., & Meadley, B. (2024). Blood lactate after pre-hospital blood transfusion for major trauma by helicopter emergency medical services. *Vox Sang*, 119(5), 460-466. <https://doi.org/10.1111/vox.13598>

Mitra, B., Wake, E., Talarico, C., Czuchwicki, S., Koolstra, C., Campbell, D.,...Winearls, J. (2024). Resuscitation of adult shocked trauma patients using major haemorrhage protocol guided by viscoelastic haemostatic assays versus formulaic approach. *Transfus Med*, 34(6), 514-519.

<https://doi.org/10.1111/tme.13109>

Mo, A., Wood, E., & McQuilten, Z. (2025). Platelet transfusion. *Curr Opin Hematol*, 32(1), 14-21. <https://doi.org/10.1097/MOH.0000000000000843>

Mo, A., Wood, E., Shortt, J., Charlton, A., Evers, D., Hoeks, M.,...McQuilten, Z. (2024). Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes. *Transfusion*.

<https://doi.org/10.1111/trf.17706>

Morrow, G. B., Flannery, S., Charles, P. D., Heilig, R., Feller, T., McQuilten, Z.,...Curry, N. (2024). A novel method to quantify fibrin-fibrin and fibrin- α . *J Thromb Haemost*, 22(6), 1758-1771. <https://doi.org/10.1016/j.jtha.2024.03.001>

Orman, Z., Reade, M. C., Marks, D. C., Howe, B. D., Bailey, M., Carrandi, A.,...Higgins, A. M. (2025). Cost-Effectiveness of Cryopreserved vs Liquid-Stored Platelets for Managing Surgical Bleeding. *JAMA Netw Open*, 8(12), e2554363.

<https://doi.org/10.1001/jamanetworkopen.2025.54363>

- Reade, M. C., Marks, D. C., Howe, B. D., Bailey, M. J., Bannon, P. G., Eastwood, G. M.,...Cryopreserved vs Liquid Platelets II (CLIP-II) Investigators, t. A. a. N. Z. I. C. S. C. T. G., the Australian and New Zealand College of Anaesthetists Clinical Trials Network, and the Australasian Society of Cardiac and Thoracic Surgeons. (2025). Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial. *JAMA*.
<https://doi.org/10.1001/jama.2025.23355>
- Rodday, A. M., Parsons, S. K., Cui, Z. J., Xiang, Q., Counsell, N., Rossetti, S.,...Evens, A. M. (2024a). *Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium 2024 BLOOD Annual Scientific Meeting*, Brisbane, Australia.
<https://ashpublications.org/blood/article/144/Supplement%201/567/530246/Creation-of-a-Multistate-Model-to-Improve>
- Rodday, A. M., Parsons, S. K., Cui, Z. J., Xiang, Q., Counsell, N., Rossetti, S.,...Evens, A. M. (2024b). *Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium 2024 American Society of Hematology Annual Meeting*, San Diego, United States.
<https://www.sciencedirect.com/science/article/pii/S0006497124033147>
- Rodday, A. M., Radford, J., Maurer, M. J., Upshaw, J., Counsell, N., Rossetti, S.,...Evens, A. M. (2024). *Development and validation of the Early stage (ES) classic Hodgkin Lymphoma (cHL) International Prognostication Index (E-HIPI): an individualized prediction model for progression-free survival (PFS) utilizing objective and continuous variables*. 2024 International Symposium on Hodgkin Lymphoma, Cologne, Germany. <https://www.hodgkinsymposium.org/abstracts-publications/775>
- Shaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C.,...Hawkes, E. A. (2024). Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. *eJHaem*, 5(2), 325-332.
<https://doi.org/10.1002/jha2.870>
- Singh, J., Li, N., Ashrafi, E., Thao, L. T. P., Curtis, D. J., Wood, E. M., & McQuilten, Z. K. (2024). Clonal hematopoiesis of indeterminate potential as a prognostic factor: a systematic review and meta-analysis. *Blood Adv*, 8(14), 3771-3784.
<https://doi.org/10.1182/bloodadvances.2024013228>
- Smyth, E., Swan, D., Wellard, C., Chung, E., Cheah, C., Hawkes, E.,...Hertzberg, M. (2024). *High-risk diffuse large B-cell lymphoma in young patients: A retrospective registry study of management practices and outcomes in Australia 2024 BLOOD Annual Scientific Meeting*, Brisbane (Australia).
https://secure.tcc.co.nz/ei/images/BLOOD24/Blood_Supplement.pdf#page=327
- Sungur, S., Yao, Y., Wellard, C., Chung, E., Morgan, S., Lee, D.,...Johnston, A. M. (2024). *Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A*

Lymphoma and Related Diseases Registry Study 2024 American Society of Hematology Annual Meeting & Exposition, San Diego, United States.
<https://ash.confex.com/ash/2024/webprogram/Paper206277.html>

Townsend, M., Maryuningsih Soedarmono, Y. S., Narayan, S., Ashford, P., Wood, E. M., & Whitaker, B. I. (2024). Haemovigilance resources available for everyone: A report from the International Haemovigilance Tools Collaborative Project. *Vox Sang*, 119(3), 277-281. <https://doi.org/10.1111/vox.13570>

van Haeren, M. M. T., Raasveld, S. J., de Bruin, S., Reuland, M. C., van den Oord, C., Schenk, J.,...Group, I. S. (2025). Plasma transfusion in the intensive care unit. *Transfusion*, 65(1), 73-87. <https://doi.org/10.1111/trf.18071>

Viiala, N. O., Range, H., Chung, E., Wellard, C., Bosco, A., Kempler, L.,...Hawkes, E. A. (2024). *Platinum substitution in salvage chemotherapy for relapsed/refractory non-Hodgkin lymphoma: a LaRDR Study* 2024 BLOOD Annual Scientific Meeting, Brisbane (Australia).
https://secure.tcc.co.nz/ei/images/BLOOD24/Blood_Supplement.pdf#page=301

Wang, L., Chung, E., Wellard, C., Barraclough, A., Campbell, B., Chong, G.,...Hawkes, E. A. (2024a). *Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive literature review* 2024 European Hematology Association Congress, <https://doi.org/10.1002/hem3.104>

Wang, L., Chung, E., Wellard, C., Barraclough, A., Campbell, B. A., Chong, G.,...Hawkes, E. A. (2024b). *The definition and use of bulk disease in phase 3 lymphoma trials: a comprehensive literature review* 2024 BLOOD Annual Scientific Meeting, Brisbane (Australia).
https://secure.tcc.co.nz/ei/images/BLOOD24/Blood_Supplement.pdf#page=301

Wood, E. M., Whitaker, B. I., Townsend, M., & Narayan, S. (2024). How we forecast tomorrow's haemovigilance. *Transfus Clin Biol*, 31(2), 114-118.
<https://doi.org/10.1016/j.tracli.2024.03.001>

Yao, Y., Sungur, S., Wellard, C., Chung, E., Morgan, S., Lee, D.,...Johnston, A. M. (2024). *Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study* 2024 American Society of Hematology Annual Meeting, San Diego (United States).
<https://doi.org/10.1182/blood-2024-206277>

Yao, Y., Sungur, S., Wellard, C., Chung, E., Morgan, S., Lee, D.,...Armytage, T. (2024). *Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study* 2024 American Society of Hematology Annual Meeting & Exposition, San Diego, United States.
<https://ash.confex.com/ash/2024/webprogram/Paper202797.html>

Zhao, S., Wellard, C., Moore, E., Spencer, A., Quach, H., Ho, J. P.,...Rajagopal, R. (2025). Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From

the Australian and New Zealand Myeloma and Related Diseases Registry. *Clin Lymphoma Myeloma Leuk.*, 26(1), 49-56.
<https://doi.org/10.10162025.08.004./j.clml>

2023

- Adhikari, N. K. J., Hashmi, M., Tirupakuzhi Vijayaraghavan, B. K., Haniffa, R., Beane, A., Webb, S. A., . . . The LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group., and the REMAPCAP Investigators. (2023). Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials. *JAMA*. doi:10.1001/jama.2023.21407
- Aubron, C., Chapalain, X., Bailey, M., Board, J., Buhr, H., Cartwright, B., . . . McQuilten, Z. (2023). Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial. *Crit Care Explor*, 5(11), e0999. doi:10.1097/CCE.0000000000000999
- Baggio, D., Fox, L. C., Wood, E. M., Aditya, R. N., Goldman, M., van den Berg, K., . . . Dunbar, N. (2023). International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Summary. *Vox Sang*, 118(12), 1115-1121. doi:10.1111/vox.13549
- Baggio, D., Fox, L. C., Wood, E. M., Aditya, R. N., Goldman, M., van den Berg, K., . . . Dunbar, N. (2023). International Forum on Blood Donation in Individuals with Current, Past or Germline Predisposition to Malignancy: Responses. *Vox Sang*, 118(12), 1122-1144. doi:10.1111/vox.13550
- Barracough, A., England, J. T., Villa, D., Wight, J., Hapgood, G., Conn, J., . . . Hawkes, E. A. (2023). Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. *Haematologica*, 108(9), 2444-2453. doi:10.3324/haematol.2022.281375
- Barracough, A., Hawkes, E., Sehn, L. H., & Smith, S. M. (2023). Diffuse large B-cell lymphoma. *Hematol Oncol*. doi:10.1002/hon.3202
- Barracough, A., & Hawkes, E. A. (2023). Antibody and immunotherapy in diffuse large B-cell lymphoma. *Semin Hematol*. doi:10.1053/j.seminhematol.2023.11.001
- Carson, J. L., Stanworth, S. J., Guyatt, G., Valentine, S., Dennis, J., Bakhtary, S., . . . Pagano, M. B. (2023). Red Blood Cell Transfusion: 2023 AABB International Guidelines. *JAMA*. doi:10.1001/jama.2023.12914
- Chai, K. L., Wong, J. W. K., Weinkove, R., Keegan, A., Crispin, P. J., Stanworth, S. J., . . . McQuilten, Z. (2023). Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. *Blood Adv*, 7(1), 20-31. doi:10.1182/bloodadvances.2022008073

- Evens, A. M., Rodday, A. M., Murer, M. J., Advani, R. H., Andre, M., Gallamini, A., . . . Radford, J. (2023). Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Paper presented at the 2023 American Society of Hematology Annual Meeting.
<https://ash.confex.com/ash/2023/webprogram/Paper173320.html>
- Flint, A. W. J., Brady, K., Wood, E. M., Thao, L. T. P., Hammond, N., Knowles, S., . . . George Institute for Global Health, the Australian and New Zealand Intensive Care Society Clinical Trials Group and the Blood Synergy Program., (2023). Transfusion practices in intensive care units: An Australian and New Zealand point prevalence study. *Crit Care Resusc*, 25(4), 193-200.
doi:10.1016/j.ccrj.2023.10.006
- Fox, L. C., McQuilten, Z. K., Firkin, F., Fox, V., Badoux, X., Bajel, A., . . . Wood, E. M. (2023). The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry. *Best Practice & Research Clinical Haematology*, 36(4), 101516. doi:<https://doi.org/10.1016/j.beha.2023.101516>
- Goh, Z., Latimer, M., Lewis, K. L., Cheah, C. Y., Ciaccio, P. D., Cushion, T., . . . Cochrane, T. (2023). Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study. *Clinical Lymphoma Myeloma and Leukemia*, 23(5), 370-378. doi:<https://doi.org/10.1016/j.clml.2023.01.014>
- Hapgood, G., Civallero, M., Stepanishyna, Y., Vose, J., Cabrera, M. E., Advani, R. H., . . . on behalf of the International T-Cell Project., (2023). The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. *Blood Advances*, 7(17), 5047-5054.
doi:10.1182/bloodadvances.2023010037
- Hills, T. E., Lorenzi, E., Berry, L. R., Shyamsundar, M., Al-Beidh, F., Annane, D., . . . The REMAP-CAP Investigators., (2023). Simvastatin in Critically Ill Patients with Covid-19. *N Engl J Med*. doi:10.1056/NEJMoa2309995
- Iannizzi, C., Chai, K. L., Piechotta, V., Valk, S. J., Kimber, C., Monsef, I., . . . Skoetz, N. (2023). Convalescent plasma for people with COVID-19: a living systematic review. *Cochrane Database Syst Rev*, 5(5), CD013600.
doi:10.1002/14651858.CD013600.pub6
- Kimber, C., Valk, S. J., Chai, K. L., Piechotta, V., Iannizzi, C., Monsef, I., . . . Skoetz, N. (2023). Hyperimmune immunoglobulin for people with COVID-19. *Cochrane Database Syst Rev*, 1(1), CD015167. doi:10.1002/14651858.CD015167.pub2
- Lawler, P. R., Derde, L. P. G., van de Veerdonk, F. L., McVerry, B. J., Huang, D. T., Berry, L. R., . . . Writing Committee for the REMAP-CAP Investigators., (2023). Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. *JAMA*, 329(14), 1183-1196. doi:10.1001/jama.2023.4480

- Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., . . . International CNS Prophylaxis Study Group., (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. *J Clin Oncol*, 41(35), 5376-5387. doi:10.1200/JCO.23.00365
- Lim, K. C. J., Wellard, C., Moore, E., Ninkovic, S., Chng, W. J., Spencer, A., . . . Quach, H. (2023). Impact of 1q21 gain and amplification on daratumumab-treated multiple myeloma patients: real-world data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries. <https://ash.confex.com/ash/2023/webprogram/Paper173896.html>
- Lim, S. L., Wellard, C., Moore, E., Harrison, S. J., Hang, Q., Ho, J., . . . Spencer, A. (2023). Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry. *Intern Med J*. doi:10.1111/imj.16277
- Lin, V. S., Sun, E., Yau, S., Abeyakoon, C., Seamer, G., Bhopal, S., . . . Green, L. (2023). Definitions of massive transfusion in adults with critical bleeding: a systematic review. *Crit Care*, 27(1), 265. doi:10.1186/s13054-023-04537-z
- Ludvigsen Al-Mashhadi, A., Simonsen, M. R. S., Cheah, C. Y., Amini, R.-M. A., Arboe, B., Cerhan, J. R., . . . El-Galaly, T. C. (2023). Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up. Paper presented at the 2023 American Society of Hematology Annual Meeting, San Diego, California. <https://ash.confex.com/ash/2023/webprogram/Paper173247.html>
- Mahady, S. E., Polekhina, G., Woods, R. L., Wolfe, R., Wetmore, J. B., Margolis, K. L., . . . Polkinghorne, K. R. (2023). Association Between CKD and Major Hemorrhage in Older Persons: Data From the Aspirin in Reducing Events in the Elderly Randomized Trial. *Kidney Int Rep*, 8(4), 737-745. doi:10.1016/j.ekir.2023.01.012
- Manni, M., Chiattoni, C. S., Prince, M. H., Pavlovsky, A., Tomuleasa, C., Miranda, E., . . . Luminari, S. (2023). Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0. Paper presented at the 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland. https://doi.org/10.1002/hon.3164_218
- Marschner, I. C., Jones, M., Totterdell, J. A., Mahar, R. K., Snelling, T. L., Tong, S. Y. C., on behalf of the Australasian Covid-19 Trial (ASCOT) study group., (2023). Transparent reporting of adaptive clinical trials using concurrently randomised cohorts. *BMJ Med*, 2(1), e000497. doi:10.1136/bmjmed-2023-000497
- Martynchyk, A., Chowdhury, R., Hawkes, E. A., & Keane, C. (2023). Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma. *Cancers (Basel)*, 15(21). doi:10.3390/cancers15215217
- Maurer, M., Parsons, S. K., Upshaw, J. N., Rodday, A. M., Friedberg, J. W., Gallamini, A., . . . Evens, A. M. (2023). Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from

the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Paper presented at the 2023 American Society of Hematology Annual Meeting, San Diego, California. <https://ash.confex.com/ash/2023/webprogram/Paper175079.html>

- McQuilten, Z. K., Thao, L. T. P., Pasricha, S. R., Artz, A. S., Bailey, M., Chan, A. T., . . . Wood, E.M., McNeil, J. J. (2023). Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly : A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial. *Ann Intern Med*, 176(7), 913-921. doi:10.7326/M23-0675
- McQuilten, Z. K., Venkatesh, B., Jha, V., Roberts, J., Morpeth, S. C., Totterdell, J. A., . . . Tong, S. Y. C. (2023). Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19. *NEJM Evid*, 2(2), EVIDoa2200293. doi:10.1056/EVIDoa2200293
- McQuilten, Z. K., Wood, E. M., & Medcalf, R. L. (2023). When to use tranexamic acid for the treatment of major bleeding? *J Thromb Haemost*. doi:10.1016/j.jtha.2023.10.001
- Mitra, B., Meadley, B., Bernard, S., Maegele, M., Gruen, R. L., Bradley, O., . . . Reade, M. C. (2023). Pre-hospital freeze-dried plasma for critical bleeding after trauma: A pilot randomized controlled trial. *Acad Emerg Med*, 30(10), 1013-1019. doi:10.1111/acem.14745
- Mo, A., Poynton, M., Wood, E., Shortt, J., Brunskill, S. J., Doree, C., . . . McQuilten, Z. (2023). Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review. *Blood Rev*, 61, 101114. doi:10.1016 j.blre.2023.101114
- Mo, A., Weinkove, R., Wood, E. M., Shortt, J., Johnston, A., McQuilten, Z. K., on behalf of the Australasian Leukaemia and Lymphoma Group Supportive Care Scientific Working Party., (2023). Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey. *Eur J Haematol*. doi:10.1111/ejh.14156
- Mo, A., Wood, E., Shortt, J., Hu, E., & McQuilten, Z. (2023). Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes. *Eur J Haematol*, 111(4), 592-600. doi:10.1111/ejh.14049
- Nelson, A., Ho, P. J., Haysom, H., Waters, N., Wellard, C., Chee, M., . . . Wood, E.M., on behalf of the Haemoglobinopathy Registry Investigators., (2023). Sick cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry. *Intern Med J*. doi:10.1111/imj.16297
- Nicol, J. L., Chong, J. E., McQuilten, Z. K., Mollee, P., Hill, M. M., & Skinner, T. L. (2023). Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review. *Clin Lymphoma Myeloma Leuk*, 23(2), 86-96. doi:10.1016 j.clml.2022.10.003
- Opat, S., Tedeschi, A., Hu, B., Linton, K. M., McKay, P., Leitch, S., . . . Trotman, J. (2023). Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone

- lymphoma: final analysis of the MAGNOLIA study. *Blood Adv*, 7(22), 6801-6811. doi:10.1182/bloodadvances.2023010668
- Raasveld, S. J., de Bruin, S., Reuland, M. C., van den Oord, C., Schenk, J., Aubron, C., . . . for the InPUT Study Group (2023). Red Blood Cell Transfusion in the Intensive Care Unit. *JAMA*. doi:10.1001/jama.2023.20737
- Reizine, F., Le Marec, S., Le Meur, A., Consigny, M., Berteau, F., Bodenes, L., . . . Aubron, C. (2023). Prophylactic platelet transfusion response in critically ill patients: a prospective multicentre observational study. *Crit Care*, 27(1), 373. doi:10.1186/s13054-023-04650-z
- Sanderson, B., Field, J. D., Kocaballi, A. B., Estcourt, L. J., Magrabi, F., Wood, E. M., & Coiera, E. W. (2023). Multicenter, multidisciplinary user-centered design of a clinical decision-support and simulation system for massive transfusion. *Transfusion*, 63(5), 993-1004. doi:10.1111/trf.17315
- Sanderson, B. J., Field, J. D., Kocaballi, A. B., Estcourt, L. J., Magrabi, F., Wood, E. M., & Coiera, E. (2023). Clinical decision support versus a paper-based protocol for massive transfusion: Impact on decision outcomes in a simulation study. *Transfusion*, 63(12), 2225-2233. doi:10.1111/trf.17580
- Shaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., . . . Hawkes, E. A. (2023). Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory trial-ineligible large B cell lymphoma patients: An Australian Lymphoma Registry (LaRDR) study. Paper presented at the 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland. https://onlinelibrary.wiley.com/doi/10.1002/hon.3165_572
- Shaw, B., Parker, C., Opat, S., Shortt, J., & Poon, P. (2023). Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care. *J Natl Compr Canc Netw*, 21(8), 813- 820.e811. doi:10.6004/jnccn.2023.7033
- Sparrow, R. L., Simpson, R. J., & Greening, D. W. (2023). Preparation of Cryoprecipitate and Cryo-depleted Plasma for Proteomic Research Analysis. *Methods Mol Biol*, 2628, 41-49. doi:10.1007/978-1-0716-2978-9_4
- Sparrow, R. L., Simpson, R. J., & Greening, D. W. (2023). Protocols for the Isolation of Platelets for Research and Contrast to Production of Platelet Concentrates for Transfusion. *Methods Mol Biol*, 2628, 3-18. doi:10.1007/978-1-0716-2978-9_1
- Stadler, E., Burgess, M. T., Schlub, T. E., Khan, S. R., Chai, K. L., McQuilten, Z. K., . . . Khoury, D. S. (2023). Monoclonal antibody levels and protection from COVID-19. *Nat Commun*, 14(1), 4545. doi:10.1038/s41467-023-40204-1
- Stadler, E., Chai, K. L., Schlub, T. E., Cromer, D., Khan, S. R., Polizzotto, M. N., . . . Davenport, M. P. (2023). Determinants of passive antibody efficacy in SARS-CoV-2 infection: a systematic review and meta-analysis. *Lancet Microbe*, 4(11), e883-e892. doi:10.1016/S2666-5247(23)00194-5

- Tang, A., Kim, K., Chen, F., McQuilten, Z. K., Mollee, P., Rajagopal, R., . . . Chng, W. J. (2023). A prospective, multinational study of clinical and biological factors associated with short overall survival in multiple myeloma. Paper presented at the American Society of Hematology. ash.confex.com/ash/2023/webprogram/Paper178192.html
- Tatarczuch, M., Waltham, M., Shortt, J., Polekhina, G., Hawkes, E. A., Ho, S. J., . . . Gregory, G. P. (2023). Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma. *Blood Adv*, 7(14), 3531-3539. doi:10.1182/bloodadvances.2022009412
- Townsend, M., Maryuningsih Soedarmono, Y. S., Narayan, S., Ashford, P., Wood, E. M., & Whitaker, B. I. (2023). Haemovigilance resources available for everyone: A report from the International Haemovigilance Tools Collaborative Project. *Vox Sang*. doi:10.1111/vox.13570
- Wong, E., Wellard, C., Rady, K., & Taulikar, D. (2023). Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Paper presented at the Canberra Health Annual Research Meeting 2023, Canberra, Australia. <https://charm.arinex.one/talks/real-world-data-on-lymphoma-in-adolescents-and-young-adults-ayareport-from-the-lymphoma-and-related-diseases-registry-lardr>
- Wood, E. M., Whitaker, B. I., & Townsend, M. (2023). Haemovigilance: Giving it our best SHOT! *Vox Sang*, 118(4), 260-262. doi:10.1111/vox.13411
- Yuen, H. L. A., Weinkove, R., Ullman, A., Marsh, N., Rickard, C. M., Chunilal, S., & McQuilten, Z. (2023). Central venous access device practice across haematology and oncology centres in Australia and New Zealand: a cross-sectional survey. *Intern Med J*, 53(3), 426-430. doi:10.1111/imj.16031
- Zargari, A., Cummins, K. D., Hosking, P., Pham, A., Hawkes, E., & Ting, S. B. (2023). Increased STAT expression in Reed-Sternberg cells as a potential positive prognostication biomarker in Hodgkin lymphoma. *Pathology*, 55(5), 650-655. doi:10.1016/j.pathol.2023.02.007
- Zeibi Shirejini, S., Carberry, J., McQuilten, Z. K., Burrell, A. J. C., Gregory, S. D., & Hagemeyer, C. E. (2023). Current and future strategies to monitor and manage coagulation in ECMO patients. *Thromb J*, 21(1), 11. doi:10.1186/s12959-023-00452-z

2022

- Ahern, S., Gabbe, B. J., Green, S., Hodgson, C. L., Wood, E. M., Zalcborg Oam, J. R., & Zazryn, T. (2022). Realising the potential: leveraging clinical quality registries for real world clinical research. *Med J Aust* doi:10.5694/mja2.51443
- Al-Riyami, A. Z., Burnouf, T., Wood, E. M., Devine, D. V., Oreh, A., Apelseth, T. O., . . . Group, I. C.-C. P. W. (2022). International Society of Blood Transfusion survey of

experiences of blood banks and transfusion services during the COVID-19 pandemic. *Vox Sang* doi:10.1111/vox.13256

- Badami, K. G., Neal, C., Sparrow, R. L., Wellard, C., Haysom, H. E., McQuilten, Z. K., & Wood, E. M. (2022). Red blood cell alloantibodies in the context of critical bleeding and massive transfusion. *Blood Transfus* doi:10.2450/2022.0131-22
- Baggio, D., Wellard, C., Chung, E., Taulikar, D., Keane, C., Opat, S., . . . Hawkes, E. A. (2022). Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. *Leukemia & Lymphoma* doi:10.1080/10428194.2022.2157676
- Bhopal, S., Chung, E., Wellard, C., Anderson, M., Hawkes, E., Mulligan, S., & Wood, E. (2022). Defining the demographics, clinical presentation, and management of Australian patients with chronic lymphocytic leukaemia (CLL) on the Lymphoma and Related Diseases Registry (LaRDR), 2016 to 2021. Paper presented at Blood 2022, Sydney, Australia.
- Bradbury, C. A., & McQuilten, Z. (2022). Anticoagulation in COVID-19. *Lancet* doi:10.1016/S0140-6736(21)02503-4
- Butel-Simoes, G. I., Jones, P., Wood, E. M., Spelman, D., Woolley, I. J., & Ojaimi, S. (2022). Congenital asplenia study: clinical and laboratory characterisation of adults with congenital asplenia. *Ann Hematol* doi:10.1007/s00277-022-04765-3
- Chai, K., Chung, E., Cheah, C., Crassini, K., Crispin, P., Cushion, T., . . . McQuilten, Z. (2022). Infection patterns and outcomes in patients with newly diagnosed CLL and NHL – Preliminary results from the Immunoglobulin use and Outcomes in CLL and NHL (ICAN) study. Paper presented at Blood 2022, Sydney, Australia.
- Chai, K. L., Wellard, C., Aoki, N., Moore, E. M., Auguston, B., Bapat, A., . . . McQuilten, Z. K. (2022). Variation in use of immunoglobulin (Ig) and impact on survival in multiple myeloma: A report from the Australia/New Zealand (ANZ) and Asia-Pacific (APAC) myeloma and related diseases registries (MRDR). Paper presented at Blood 2022, Sydney, Australia.
- de Vos, T. W., Winkelhorst, D., Arnadottir, V., van der Bom, J. G., Canals Suris, C., Caram-Deelder, C., . . . Lopriore, E. (2022). Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study. *Lancet Haematol* doi:10.1016/S2352-3026(22)00243-5
- Flint, A. W., Brady, K., Reade, M. C., Knowles, S., Hammond, N. E., Wood, E. M., & McQuilten, Z. K. (2022). Transfusion practices in Australian and New Zealand intensive care units: A point prevalence study. Paper presented at Blood 2022, Sydney, Australia.
- Goh, Z., Latimer, M., Lewis, K., Cheah, C., Di Ciaccio, P., Cushion, T., . . . Cochrane, T. (2022). Characteristics and Outcomes of Elderly Patients with classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Diseases Registry (LaRDR) Study. Paper presented at the Blood 2022, Sydney, Australia.

- Goh, Z., Latimer, M., Lewis, K. L., Cheah, C. Y., Ciaccio, P. D., Cushion, T., . . . Cochrane, T. (2022). Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study. Paper presented at ASH, New Orleans, Louisiana.
<https://ash.confex.com/ash/2022/webprogram/Paper156782.html>
- Green, L., Stanworth, S., McQuilten, Z., Lin, V., Tucker, H., Jackson, B., . . . Dunbar, N. (2022). International Forum on the Management of Major Haemorrhage: Responses. *Vox Sang* doi:10.1111/vox.13243
- Green, L., Stanworth, S., McQuilten, Z., Lin, V., Tucker, H., Jackson, B., . . . Dunbar, N. (2022). International Forum on the Management of Major Haemorrhage: Summary. *Vox Sang* doi:10.1111/vox.13244
- Haysom, H., Waters, J., Wellard, C., Crichton, G., Henry, A., Williams, B., . . . McQuilten, Z. K. (2022). Neonatal alloimmune thrombocytopenia (NAIT) is uncommon, but still important: Patient characteristics, management and outcomes from the Australian NAIT registry. Paper presented at Blood 2022, Sydney, Australia.
- Hirsch, C., Park, Y. S., Piechotta, V., Chai, K. L., Estcourt, L. J., Monsef, I., . . . Kreuzberger, N. (2022). SARS-CoV-2- neutralising monoclonal antibodies to prevent COVID-19. *Cochrane Database Syst Rev* doi:10.1002/14651858.CD014945.pub2
- Huynh, K., Wood, E., McQuilten, Z., Brady, K., Smith, K., Spencer, A., . . . Haysom, H. (2022). Building a National Transfusion Dataset (NTD) for Australia. Paper presented at Blood 2022, Sydney, Australia.
- LaRDR Investigators (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. *BMC Medical Research Methodology*
<https://doi.org/10.1186/s12874-022-01728-0>
- Irving, A. H., Harris, A., Petrie, D., Higgins, A., Smith, J. A., Tran, L., . . . McQuilten, Z. K. (2022). Economic Evaluation of National Patient Blood Management Clinical Guidelines in Cardiac Surgery. *Value Health* doi:10.1016/j.jval.2021.07.014
- Kiely, P., Seed, C. R., Gambhir, M., Cheng, A. C., McQuilten, Z. K., & Wood, E. M. (2022). West Nile virus transfusiontransmission risk in Australia associated with a seasonal outbreak in the United States. *Transfusion* doi:10.1111/trf.17094
- Lucas, R., Dennington, P., Wood, E., Murray, K. J., Cheng, A., Burgner, D., & Singh-Grewal, D. (2022). Epidemiology of Kawasaki disease in Australia using two nationally complete datasets. *J Paediatr Child Health* doi:10.1111/jpc.15816
- McQuilten, Z., Wellard, C., Moore, E., Augustson, B., Bergin, K., Blacklock, H., . . . Spencer, A. (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *British Journal of Haematology* doi:10.1111/bjh.18324

- McQuilten, Z. K., Busija, L., Seymour, J. F., Stanworth, S., Wood, E. M., Kenealy, M., . . . Lymphoma, G. (2022). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. *Leuk Lymphoma* doi:10.1080/10428194.2021.2012664
- Mitra, B., Wood, E. M., & Reade, M. C. (2022). Whole blood for trauma resuscitation? *Injury* doi:10.1016/j.injury.2022.04.001
- Mo, A., Weinkove, R., Shortt, J., Johnson, A., Wood, E. M., McQuilten, Z. K., & Party, A. S. C. W. (2022). Making decisions about platelet transfusions in patients with myelodysplastic syndromes (MDS): A clinician survey to inform future clinical trials. Paper presented at Blood 2022, Sydney, Australia.
- Moore, E. M., Blacklock, H., Wellard, C., Spearing, R., Merriman, L., Poplar, S., . . . Spencer, A. (2022). Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Clinical Lymphoma Myeloma and Leukemia* doi: 10.1016/j.clml.2022.04.004
- Morrow, G. B., Feller, T., McQuilten, Z., Wake, E., Ariëns, R. A. S., Winearls, J., . . . Curry, N. (2022). Cryoprecipitate transfusion in trauma patients attenuates hyperfibrinolysis and restores normal clot structure and stability: Results from a laboratory sub-study of the FEISTY trial. *Crit Care* doi:10.1186/s13054-022-04167-x
- Myles, P. S., Richards, T., Klein, A., Wood, E. M., Wallace, S., Shulman, M. A., . . . RELIEF Trial Investigators (2022). Postoperative anaemia and patient-centred outcomes after major abdominal surgery: a retrospective cohort study. *Br J Anaesth* doi:10.1016/j.bja.2022.06.014
- Nguyen, J., Wellard, C., Chung, E., Cheah, C. Y., Dickinson, M., Doo, N. W., . . . LaRDR Investigators (2022). Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. *Eur J Haematol.* doi:10.1111/ejh.13915
- Ratnasingam, S., Mutsando, H., Hawkes, E., Wood, E., Wellard, C., Chung, E., & Opat, S. (2022). Patient characteristics and management of aggressive lymphoma in metropolitan and non-metropolitan centres in Australia from the Lymphoma and Related Diseases Registry (LaRDR). Paper presented at Blood 2022, Sydney, Australia. REMAP-CAP Writing Committee for the
- REMAP-CAP Investigators (2022). Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA* doi:10.1001/jama.2022.2910
- Rodday, A. M., Parsons, S. K., Friedberg, J. W., Gallamini, A., Hawkes, E., Hodgson, D. C., . . . Evens, A. M. E. (2022). Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC)

Consortium. Paper presented at ASH, New Orleans, Louisiana.
ash.confex.com/ash/2022/webprogram/Paper164720.html

- Rodday, A. M., Parsons, S. K., Upshaw, J. N., Friedberg, J. W., Gallamini, A., Hawkes, E., . . . Evens, A. M. (2022). The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. *Journal of Clinical Oncology* doi:10.1200/jco.22.02473
- Shaw, B., Wood, E., McQuilten, Z., Callum, J., Romon, I., Sanroma, P., . . . Dunbar, N. (2022). International Forum on Home-Based Blood Transfusion: Responses. *Vox Sang* doi:10.1111/vox.13199
- Shaw, B., Wood, E., McQuilten, Z., Callum, J., Romon, I., Sanroma, P., . . . Dunbar, N. (2022). International Forum on Home-Based Blood Transfusion: Summary. *Vox Sang* doi:10.1111/vox.13200
- Shaw, B., Wood, E. M., Callum, J., & McQuilten, Z. K. (2022). Home Delivery: Transfusion Services When and Where They Are Needed. *Transfus Med Rev* doi:10.1016/j.tmr.2022.06.003
- Tan, J. L. C., Wellard, C., Moore, E. M., Mollee, P., Rajagopal, R., Quach, H., . . . MRDR Investigators (2022). The second revision of the International Staging System (R2-ISS) stratifies progression-free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. *British Journal of Haematology*. doi: 10.1111/bjh.18536
- Tan, J. L. C., Wellard, C., Moore, E. M., Mollee, P., Rajagopal, R., Quach, H., . . . MRDR Investigators (2022). Validation of the second revision of the International Staging System in a real-world myeloma population (R2-ISS): A Myeloma and Related Diseases Registry (MRDR) Study. Paper presented at Blood 2022, Sydney, Australia.
- Tong, S. Y. C., Mora, J., Bowen, A. C., Cheng, M. P., Daneman, N., Goodman, A. L., . . . SNAP Study Group (2022). The Staphylococcus aureus Network Adaptive Platform Trial protocol: New tools for an old foe. *Clin Infect Dis* doi:10.1093/cid/ciac476
- Willers, A., Swol, J., Buscher, H., McQuilten, Z., van Kuijk, S. M. J., Ten Cate, H., . . . Tonna, J. E. (2022). Longitudinal Trends in Bleeding Complications on Extracorporeal Life Support Over the Past Two Decades-Extracorporeal Life Support Organization Registry Analysis. *Crit Care Med* doi:10.1097/CCM.0000000000005466
- Willers, A., Swol, J., van Kuijk, S. M. J., Buscher, H., McQuilten, Z., Ten Cate, H., . . . Tonna, J. E. (2022). HEROES VA: HEMorrhagic cOmplications in veno-arterial Extracorporeal life Support: Development and internal validation of a multivariable prediction model in adult patients. *Artif Organs* doi:10.1111/aor.14340

- Wong, E., Wellard, C., Rady, K., & Talaulikar, D. (2022). Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Paper presented at Blood 2022, Sydney, Australia.
- Zhang, L., Li, H., Su, S., Wood, E. M., Ma, T., Sun, Y., . . . Yang, J. (2022). Cohort Profile: The Shaanxi Blood Donor Cohort in China. *Front Cardiovasc Med* doi:10.3389/fcvm.2022.841253

2021

- Al-Riyami, A. Z., Schäfer, R., van den Berg, K., Bloch, E. M., Estcourt, L. J., Goel, R., . . . So-Osman, C. (2021). Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. *Vox Sang* doi:10.1111/vox.12973
- Aubron, C., Hourmant, B., Menguy, J., & Sparrow, R. L. (2021). Transfusion-related respiratory complications in intensive care: A diagnosis challenge. *Transfus Clin Biol* doi:10.1016/j.tracli.2021.09.007
- Axfors, C., Janiaud, P., Schmitt, A. M., Van't Hooft, J., Smith, E. R., Haber, N. A., . . . Hemkens, L. G. (2021). Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. *BMC Infect Dis* doi:10.1186/s12879-021-06829-7
- Baggio, D. (2021). Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian context: an analysis of the Lymphoma and Related Diseases Registry. Paper presented at the 13th Annual T-cell Lymphoma Forum 2021.
- Baggio, D., St George, G., Chung, E., Waters, N., Wood, E., McQuilten, Z., . . . Opat, S. (2021). Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry. Paper presented at BLOOD 2021, Adelaide, Australia. https://secure.tcc.co.nz/ei/images/BLOOD21/Abstract_Bookv3.pdf
- Baggio, D., St George, G., Chung, E., Waters, N., Wood, E., McQuilten, Z., . . . Hawkes, E. (2021). Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry. Paper presented at BLOOD 2021, Adelaide, Australia. https://secure.tcc.co.nz/ei/images/BLOOD21/Abstract_Bookv3.pdf
- Baggio, D., St George, G., Chung, E., Waters, N., Wood, E., McQuilten, Z., . . . Shortt, J. (2021). Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry (LaRDR). Paper presented at the BLOOD 2021, Adelaide, Australia. https://secure.tcc.co.nz/ei/images/BLOOD21/Abstract_Bookv3.pdf
- Bergin, K., Wellard, C., Augustson, B., Cooke, R., Blacklock, H., Harrison, S. J., . . . Related Diseases, R. (2021). Realworld utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related

diseases registry (MRDR). Bone Marrow Transplantation. doi:10.1038/s41409-021-01308-8

- Bergin, K., Wellard, C., Moore, E., McQuilten, Z., Blacklock, H., Harrison, S. J., . . . Spencer, A. (2021). The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). *Clinical Lymphoma, Myeloma and Leukemia* doi:10.1016/j.clml.2021.01.016
- Boyle, S., Wellard, C., Moore, E. M., Blacklock, H., Harrison, S. J., Ho, P. J., . . . MRDR Investigators (2021). Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. *European Journal of Haematology* doi:10.1111/ejh.13677
- Federico, M., Chiattoni, C. S., Prince, H. M., Pavlovsky, A., Manni, M., Civallero, M., . . . Luminari, S. (2021). SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0. *Hematological Oncology* doi:10.1002/hon.135_2880
- Federico, M., Chiattoni, C. S., Prince, H. M., Pavlovsky, A., Manni, M., Civallero, M., . . . Luminari, S. (2021). Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0. Paper presented at the 16th International Conference on Malignant Lymphoma, Lugano, Switzerland.
- Fulford, T. S., Van, H., Gherardin, N. A., Zheng, S., Ciula, M., Drummer, H. E., . . . Godfrey, D. I. (2021). A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. *EBioMedicine*, doi:10.1016/j.ebiom.2021.103729
- Gordon, S. F., Clothier, H. J., Morgan, H., Buttery, J. P., Phuong, L. K., Monagle, P., . . . Vic, S. I. S. i. (2021). Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. *Vaccine* doi:10.1016/j.vaccine.2021.10.030
- Ket, S. N., Sparrow, R. L., McQuilten, Z. K., Gibson, P. R., Brown, G. J., & Wood, E. M. (2021). Critical peptic ulcer bleeding requiring massive blood transfusion: outcomes of 270 cases. *Internal Medicine Journal* doi:10.1111/imj.15009
- Kreuzberger, N., Hirsch, C., Chai, K. L., Tomlinson, E., Khosravi, Z., Popp, M., . . . Skoetz, N. (2021). SARS-CoV-2- neutralising monoclonal antibodies for treatment of COVID-19. *Cochrane Database Syst Rev* doi:10.1002/14651858.CD013825.pub2
- Mahady, S. E., Margolis, K. L., Chan, A., Polekhina, G., Woods, R. L., Wolfe, R., . . . McNeil, J. J. (2021). Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. *Gut* doi:10.1136/gutjnl-2020-321585
- McQuilten, Z. K., Flint, A. W., Green, L., Sanderson, B., Winearls, J., & Wood, E. M. (2021). Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. *Transfus Med Rev* doi:10.1016/j.tmr.2021.08.006

- Mo, A., Stanworth, S. J., Shortt, J., Wood, E. M., & McQuilten, Z. K. (2021). Red cell transfusions: Is less always best?: How confident are we that restrictive transfusion strategies should be the standard of care default transfusion practice? *Transfusion* doi:10.1111/trf.16429
- Myles, P. S., Richards, T., Klein, A., Smith, J., Wood, E. M., Heritier, S., . . . Network, A. C. T. (2021). Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial. *Am Heart J* doi:10.1016/j.ahj.2021.05.008
- Nguyen, J., St George, G., Chung, E., Waters, N., Wood, E., McQuilten, Z., . . . Hawkes, E. (2021). Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR). Paper presented at BLOOD 2021, Adelaide, Australia.
https://secure.tcc.co.nz/ei/images/BLOOD21/Abstract_Bookv3.pdf
- Opat, S., St George, G., Wellard, C., Chung, E., Berkahn, L., Cheah, C., . . . Wood, E. (2021). Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR). Paper presented at BLOOD 2021, Adelaide, Australia.
https://secure.tcc.co.nz/ei/images/BLOOD21/Abstract_Bookv3.pdf
- Piechotta, V., Iannizzi, C., Chai, K. L., Valk, S. J., Kimber, C., Dorando, E., . . . Skoetz, N. (2021). Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *Cochrane Database Syst Rev* doi:10.1002/14651858.CD013600.pub4
- Saadah, N. H., Wood, E. M., Bailey, M. J., Cooper, D. J., French, C. J., Haysom, H. E., . . . New Zealand Massive Transfusion Registry Steering, C. (2021). Age of red blood cells is not associated with in-hospital mortality in massively transfused patients. *J Trauma Acute Care Surg* doi:10.1097/TA.0000000000003192
- Sanderson, B. J., Field, J. D., Estcourt, L. J., Wood, E. M., & Coiera, E. W. (2021). Massive transfusion experience, current practice and decision support: A survey of Australian and New Zealand anaesthetists. *Anaesth Intensive Care* doi:10.1177/0310057X20974035
- Shipton, M., Wellard, C., Gayathri, S. G., Chung, E., Waters, N., McQuilten, Z., . . . Dickinson, M. (2021). Patterns of treatment and outcomes in patients with large B-cell lymphoma: The Australian real-world experience. Paper presented at BLOOD 2021, Adelaide, Australia.
https://secure.tcc.co.nz/ei/images/BLOOD21/Abstract_Bookv3.pdf
- Solves, P., Lozano, M., Zhiburt, E., Anguita Velasco, J., Maria Pérez-Corral, A., Monsalvo-Saornil, S., . . . Dunbar, N. (2021). International Forum on Transfusion Practices in Haematopoietic Stem-Cell Transplantation: Responses. *Vox Sang* doi:10.1111/vox.13021
- Winearls, J., Reade, M. C., McQuilten, Z., & Curry, N. (2021). Fibrinogen in traumatic haemorrhage. *Curr Opin Anaesthesiol* doi:10.1097/ACO.0000000000001027
- Wolfe, R., Wetmore, J. B., Woods, R. L., McNeil, J. J., Gallagher, H., Roderick, P., . . . Polkinghorne, K. R. (2021). Subgroup analysis of the ASPirin in Reducing Events

in the Elderly randomized clinical trial suggests aspirin did not improve outcomes in older adults with chronic kidney disease. *Kidney Int* doi:10.1016/j.kint.2020.08.011

REMAP-CAP Investigators (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med* doi:10.1056/NEJMoa2103417 REMAP-CAP Writing Committee for

REMAP-CAP Investigators (2021). Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA* doi:10.1001/jama.2021.18178

2020

Alves, D., Curvello, R., Henderson, E., Kesarwani, V., Walker, J. A., Leguizamon, S. C., . . . Corrie, S. R. (2020). Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans. *ACS Sens* doi:10.1021/acssensors.0c01050

Chai, K. L., Valk, S. J., Piechotta, V., Kimber, C., Monsef, I., Doree, C., . . . Skoetz, N. (2020). Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. *Cochrane Database Syst Rev* doi:10.1002/14651858.CD013600.pub3

Cheek, K. P. L., Chhetri, R., Wee, L. Y. A., Friel, O., Pham, A., Salvi, A., . . . Hiwase, D. K. (2020). The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes. *Transfusion* doi:10.1111/trf.16029

Flint, A. W., McQuilten, Z. K., Irwin, G., Rushford, K., Haysom, H. E., & Wood, E. M. (2020). Is Platelet Expiring Out of Date? A Systematic Review. *Transfus Med Rev* doi:10.1016/j.tmr.2019.08.006

Flint, A. W. J., Bailey, M., Reid, C. M., Smith, J. A., Tran, L., Wood, E. M., . . . Reade, M. C. (2020). Preoperative identification of cardiac surgery patients at risk of receiving a platelet transfusion: The Australian Cardiac Surgery Platelet Transfusion (ACSePT) risk prediction tool. *Transfusion* doi:10.1111/trf.15990

Fox, L. C., Wood, E. M., Ritchie, D. S., & Blombery, P. (2020). Diagnostic evaluation and considerations in hypocellular bone marrow failure-A focus on genomics. *Int J Lab Hematol* doi:10.1111/ijlh.13179

Ho, P. J., Moore, E. M., Wellard, C., Quach, H., Blacklock, H., Harrison, S. J., . . . Spencer, A. (2020). The Impact of SLi-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Blood* doi:10.1182/blood-2020-141511

Huynh, K., Aoki, N., Kim, K., Chng, W. J., Gan, G. G., Min, C.-K., . . . Spencer, A. (2020). The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. *Blood* doi:10.1182/blood-2020-136896

- Irving, A. H., Harris, A., Petrie, D., Higgins, A., Smith, J., & McQuilten, Z. K. (2020). Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery. *J Thorac Cardiovasc Surg* doi:10.1016/j.jtcvs.2019.08.102
- Irving, A. H., Harris, A., Petrie, D., Mortimer, D., Ghijben, P., Higgins, A., & McQuilten, Z. (2020). A systematic review and network meta-analysis of incentive- and non-incentive-based interventions for increasing blood donations. *Vox Sang* doi:10.1111/vox.12881
- Keragala, C. B., Woodruff, T. M., Liu, Z., Niego, B., Ho, H., McQuilten, Z., & Medcalf, R. L. (2020). Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement. *Front Neurol* doi:10.3389/fneur.2020.577272
- Kiely, P., Seed, C. R., Hoad, V. C., Gambhir, M., Cheng, A. C., McQuilten, Z. K., & Wood, E. M. (2020). Modeling the West Nile virus transfusion transmission risk in a nonoutbreak country associated with traveling donors. *Transfusion* doi:10.1111/trf.16060
- Lasica, M., Sparrow, R. L., Tacey, M., Pollock, W. E., Wood, E. M., McQuilten, Z. K., & Committee, m. o. t. Australian a. N. Z. M. T. Registry S. (2020). Haematological features, transfusion management and outcomes of massive obstetric haemorrhage: findings from the Australian and New Zealand Massive Transfusion Registry. *Br J Haematol* doi:10.1111/bjh.16524
- Maqbool, M. G., Tam, C. S., Morison, I. M., Simpson, D., Mollee, P., Schneider, H., . . . Talaulikar, D. (2020). A practical guide to laboratory investigations at diagnosis and follow up in Waldenstrom macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Subcommittee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. *Pathology* doi:10.1016/j.pathol.2019.11.002
- Moore, E. M., King, T. A., Wood, E. M., Ruseckaite, R., Klarica, D., Spencer, A., . . . McQuilten, Z. K. (2020). Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial. *American Journal of Hematology* doi:10.1002/ajh.25815
- Sanderson, B., Coiera, E., Asrianti, L., Field, J., Estcourt, L. J., & Wood, E. M. (2020). How well does your massive transfusion protocol perform? A scoping review of quality indicators. *Blood Transfus* doi:10.2450/2020.0082- 20
- Stanworth, S. J., Killick, S., McQuilten, Z. K., Karakantza, M., Weinkove, R., Smethurst, H., . . . Investigators, R. (2020). Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. *Br J Haematol* doi:10.1111/bjh.16347
- Valk, S. J., Piechotta, V., Chai, K. L., Doree, C., Monsef, I., Wood, E. M., . . . Skoetz, N. (2020). Convalescent plasma or hyperimmune immunoglobulin for people with

COVID-19: a rapid review. Cochrane Database Syst Rev
doi:10.1002/14651858.CD013600

- Van Remoortel, H., Aranko, K., Mueller, M. M., De Buck, E., Devine, D., Folléa, G., . . . Seifried, E. (2020). The systematic use of evidence-based methodologies and technologies enhances shared decision-making in the 2018 International Consensus Conference on Patient Blood Management. *Vox Sang* doi:10.1111/vox.12852
- Weinkove, R., McQuilten, Z. K., Adler, J., Agar, M. R., Blyth, E., Cheng, A. C., . . . Teh, B. W. (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. *Med J Aust* doi:10.5694/mja2.50607
- Wood, E. M., & McQuilten, Z. K. (2020). Outpatient transfusions for myelodysplastic syndromes. *Hematology Am Soc Hematol Educ Program* doi:10.1182/hematology.2020000103
- Yazer, M. H., Jackson, B., Pagano, M., Rahimi-Levene, N., Peer, V., Bueno, J. L., . . . Lozano, M. (2020). Vox Sanguinis International Forum on Hospital Transfusion Services' Response to COVID-19: Responses. *Vox Sang* doi:10.1111/vox.12944
- Yazer, M. H., Jackson, B., Pagano, M., Rahimi-Levene, N., Peer, V., Bueno, J. L., . . . Lozano, M. (2020). Vox Sanguinis International Forum on transfusion services' response to COVID-19: Summary. *Vox Sang* doi:10.1111/vox.12943

2019

- Aoki, N., Moore, E. M., Wood, E. M., McQuilten, Z. K., Wellard, C., & Spencer, A. (2019). Real-World Treatment Patterns and Clinical Outcomes in Multiple Myeloma in the Asia-Pacific Region: Methodology and Preliminary Results of the Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR). *Blood* doi:10.1182/blood2019-124256
- Aubron, C., McQuilten, Z., Bailey, M., Board, J., Buhr, H., Cartwright, B., . . . endorsed by the ECMONet (2019). LowDose Versus Therapeutic Anticoagulation in Patients on Extracorporeal Membrane Oxygenation: A Pilot Randomized Trial. *Crit Care Med* doi:10.1097/CCM.0000000000003780
- Barracough, A., Hawkes, E., & Churilov, L. (2019). Utility of GELF criteria in treatment decisions for follicular lymphoma (FL) treated in clinical practice. Paper presented at Blood 2019, Perth, Australia.
<https://hsanz.org.au/resources/Documents/Blood%20Abstract%20Supplement/Blood%202019%20abstract%20supplement.pdf>
- Barracough, A., Yoo, E., Cheah, C., Talaulikar, D., Nguyen, B., Turner, M., . . . Hawkes, E. (2019). The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. *Blood* doi:10.1182/blood-2019-129294
- Burns, K. E., Haysom, H. E., Higgins, A. M., Waters, N., Tahiri, R., Rushford, K., . . . Wood, E. M. (2019). A timedriven, activity-based costing methodology for determining

the costs of red blood cell transfusion in patients with beta thalassaemia major. *Transfus Med* doi:10.1111/tme.12523

Clucas, D. B., Fox, L. C., Wood, E. M., Hong, F. S., Gibson, J., Bajel, A., . . . on behalf of the Australian AAR Steering Committee (2019). Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. *Intern Med J* doi:10.1111/imj.14140

Estcourt, L. J., McQuilten, Z., Powter, G., Dyer, C., Curnow, E., Wood, E. M., . . . on behalf of the TREATT Trial Collaboration (2019). The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. *Trials* doi:10.1186/s13063-019-3663-2

Ho, P. J., Moore, E. M., McQuilten, Z. K., Wellard, C., Bergin, K., Augustson, B., . . . Spencer, A. (2019). Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. *Clinical Lymphoma, Myeloma and Leukemia*, 19(8), e415-e424. doi:10.1016/j.clml.2019.05.010

Irving, A., Higgins, A., Ady, B., Bellomo, R., Cooper, D. J., French, C., . . . on behalf of the TRANSFUSE Investigators and ANZICS CTG (2019). Fresh Red Cells for Transfusion in Critically Ill Adults: An Economic Evaluation of the Standard Issue Transfusion Versus Fresher Red-Cell Use in Intensive Care (TRANSFUSE) Clinical Trial. *Crit Care Med* doi:10.1097/CCM.0000000000003781

Keir, A. K., New, H., Robitaille, N., Crighton, G. L., Wood, E. M., & Stanworth, S. J. (2019). Approaches to understanding and interpreting the risks of red blood cell transfusion in neonates. *Transfus Med* doi:10.1111/tme.12575

Ket, S. N., Sparrow, R. L., McQuilten, Z. K., Tacey, M., Gibson, P. R., Brown, G. J., & Wood, E. M. (2019). Clinical coding data algorithm to categorize type of gastrointestinal bleeding as a primary reason for massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. *Vox Sanguinis* doi:10.1111/vox.12840

Lim, M. S., Indran, T., Cummins, A., Bennett, A., Wood, E., Brown, S., . . . Chunilal, S. (2019). Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study. *Semin Thromb Hemost* doi:10.1055/s-0038-1676320

McQuilten, Z. K., & Cooper, D. J. (2019). Age of Red Blood Cells for Transfusion in Critically Ill Pediatric Patients. *JAMA* doi:10.1001/jama.2019.17476

McQuilten, Z. K., Higgins, A. M., Burns, K., Chunilal, S., Dunstan, T., Haysom, H. E., . . . Wood, E. M. (2019). The cost of blood: a study of the total cost of red blood cell transfusion in patients with β -thalassemia using timedriven activity-based costing. *Transfusion* doi:10.1111/trf.15558

- Mueller, M. M., Van Remoortel, H., Meybohm, P., Aranko, K., Aubron, C., Burger, R., . . . Group, I. P. F. (2019). Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. *JAMA* doi:10.1001/jama.2019.0554
- Ratnasingam, S., Casan, J., Shortt, J., Hawkes, E., Gilbertson, M., McQuilten, Z., . . . Opat, S. (2019). Cytarabinebased induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. *Sci Rep*, doi:10.1038/s41598-019-49776-9
- Spencer, A., Mollee, P., Blacklock, H. A., Harrison, S., Quach, H., Ho, P. J., . . . Wellard, C. (2019). Real-World Outcome for Newly Diagnosed Patients with Functional High-Risk Myeloma - a Myeloma and Related Diseases Registry Analysis. *Blood* doi:10.1182/blood-2019-129431
- St George, G., Wellard, C., Berkahn, L., Cheah, C., Dickinson, M., Gandhi, M., . . . Opat, S. (2019). The Lymphoma and Related Diseases Registry (LaRDR): A post-pilot update. Paper presented at Blood 2019, Perth, Australia.
<https://hsanz.org.au/resources/Documents/Blood%20Abstract%20Supplement/Blood%202019%20abstract%20supplement.pdf>
- Stephanie Clugston, D. H., Shane Gangatharan. (2019). Decision-making in CNS prophylaxis for DLBCL in a single institution. Paper presented at Blood 2019, Perth, Australia.
<https://hsanz.org.au/resources/Documents/Blood%20Abstract%20Supplement/Blood%202019%20abstract%20supplement.pdf>
- Tohidi-Esfahani, I., Warden, A., Malunis, E., DeNardis, P., Bomsztyk, J., D'Sa, S., . . . Trotman, J. (2019). WhiMSICAL (Waldenström's Macroglobulinemia Study In CARt-wheel): A Global Patient-derived Data Registry mapping treatment and quality of life data. Paper presented at the ICML 2019, Lugano, Switzerland.
- Tohidi-Esfahani, I., Warden, A., Malunis, E., DeNardis, P., Bomsztyk, J., D'Sa, S., . . . Trotman, J. (2019). WhiMSICAL (WALDENSTRÖM'S MACROGLOBULINEMIA STUDY INVOLVING CARt-wheel): A GLOBAL PATIENT-DERIVED DATA REGISTRY MAPPING TREATMENT AND QUALITY OF LIFE. *Hematological Oncology* doi:10.1002/hon.46_2630
- Wong, J., Wood, E. M., Crispin, P., Weinkove, R., McQuilten, Z. K., on behalf of the ALLG Supportive Care Group (2019). Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. *Intern Med J* doi:10.1111/imj.14082
- Wood, E. M., Ang, A. L., Bisht, A., Bolton-Maggs, P. H., Bokhorst, A. G., Flesland, O., . . . Whitaker, B. I. (2019). International haemovigilance: what have we learned and what do we need to do next? *Transfusion Medicine*, doi:10.1111/tme.12582
- Yazer, M. H., Delaney, M., Doughty, H., Dunbar, N. M., Al-Riyami, A. Z., Triulzi, D. J., . . . Emery, S. P. (2019). It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. *Transfusion* doi:10.1111/trf.15569

Yoo, E., Lewis, K., Joske, D., Cull, G., Crawford, J., Radeski, D., . . . Cheah, C. (2019). Treatment patterns and outcomes of patients with follicular lymphoma (FL) at Sir Charles Gairdner Hospital (SCGH): An analysis of data from the Lymphoma and related diseases registry (LarDR). Paper presented at Blood 2019, Perth, Australia.
<https://hsanz.org.au/resources/Documents/Blood%20Abstract%20Supplement/Blood%202019%20abstract%20supplement.pdf>

2018

Aubron, C., Flint, A. W. J., Ozier, Y., & McQuilten, Z. (2018). Platelet storage duration and its clinical and transfusion outcomes: a systematic review. *Crit Care* doi:10.1186/s13054-018-2114-x

Aubron, C., Kandane-Rathnayake, R. K., Andrianopoulos, N., Westbrook, A., Engelbrecht, S., Ozolins, I., . . . ANZICS CTG (2018). Day or overnight transfusion in critically ill patients: does it matter? *Vox Sang* doi:10.1111/vox.12635

Colman, K. S., Wood, E. M., De La Salle, B., Stanworth, S. J., & Pasricha, S. R. (2018). Heterogeneous hemoglobin lower thresholds in clinical laboratories. *Am J Hematol* doi:10.1002/ajh.25080

Dickinson, M., Hawkes, E., Berkahn, L., Cheah, C., Gandhi, M., Giri, P., . . . Opat, S. (2018). High rates of early treatment failure in diffuse large B-cell lymphoma: early results from the Lymphoma and Related Diseases Registry. Paper presented at Blood 2018, Brisbane, Australia.
<https://www.hsanz.org.au/resources/Documents/Blood%20Abstract%20Supplement/Blood%202018%20abstract%20supplement.pdf>

Dyer, C., Alquist, C. R., Cole-Sinclair, M., Curnow, E., Dunbar, N. M., Estcourt, L. J., . . . on behalf of the BEST Collaborative (2018). A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy. *Vox Sang* doi:10.1111/vox.12627

Flint, A. W. J., McQuilten, Z. K., & Wood, E. M. (2018). Massive transfusions for critical bleeding: is everything old new again? *Transfus Med* doi:10.1111/tme.12524

Fox, L. C., Cohn, S. J., Kausman, J. Y., Shortt, J., Hughes, P. D., Wood, E. M., . . . Barbour, T. D. (2018). Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. *Nephrology (Carlton)* doi:10.1111/nep.13234

Fox, L. C., Cohn, S. J., Kausman, J. Y., Shortt, J., Hughes, P. D., Wood, E. M., . . . Barbour, T. D. (2018). Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. *Intern Med J* doi:10.1111/imj.13804

- Gipson, J. S., Wood, E. M., Cole-Sinclair, M. F., McQuilten, Z., Waters, N., & Woodford, N. W. (2018). Major haemorrhage fatalities in the Australian national coronial database. *Emerg Med Australas* doi:10.1111/1742- 6723.12915
- Keragala, C. B., Draxler, D. F., McQuilten, Z. K., & Medcalf, R. L. (2018). Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways. *Br J Haematol*, 180(6), 782-798. doi:10.1111/bjh.15062
- Kiely, P., Hoad, V. C., & Wood, E. M. (2018). False positive viral marker results in blood donors and their unintended consequences. *Vox Sang* doi:10.1111/vox.12675
- Margolis, K. L., Mahady, S. E., Nelson, M. R., Ives, D. G., Satterfield, S., Britt, C., . . . Wood, E. M. (2018). Development of a standardized definition for clinically significant bleeding in the ASPIrin in Reducing Events in the Elderly (ASPREE) trial. *Contemp Clin Trials Commun* doi:10.1016/j.conctc.2018.05.015
- McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., . . . Group, A. I. (2018). Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. *N Engl J Med* doi:10.1056/NEJMoa1805819
- McQuilten, Z. K., Crichton, G., Brunskill, S., Morison, J. K., Richter, T. H., Waters, N., . . . Wood, E. M. (2018). Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Results from a Systematic Review. *Transfus Med Rev* doi:10.1016/j.tmr.2017.06.003
- McQuilten, Z. K., French, C. J., Nichol, A., Higgins, A., & Cooper, D. J. (2018). Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. *Transfus Med Rev*, 32(2), 77-88. doi:10.1016/j.tmr.2018.02.002
- Ninkovic, S., McQuilten, Z., Gotmaker, R., Newcomb, A. E., & Cole-Sinclair, M. F. (2018). Platelet transfusion is not associated with increased mortality or morbidity in patients undergoing cardiac surgery. *Transfusion* doi:10.1111/trf.14561
- Pavenski, K., Stanworth, S., Fung, M., Wood, E. M., Pink, J., Murphy, M. F., . . . for the ICTMG (2018). Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review. *Transfus Med Rev* doi:10.1016/j.tmr.2018.05.004
- Rowell, L., Lade, S., Kumar, B., Juneja, S., Morey, A., Jain, S., . . . Talaulikar, D. (2018). A national pathology review committee for the lymphoma and related diseases registry. *Pathology* doi:10.1016/j.pathol.2017.12.302
- Xu K, R. L., Tahir F, Hall L, Opat S, Wood E, McQuilten Z, Haurat J, Scott C, Trotman J, Tohidi-Esfahani I. (2018). WhiMSICAL (Waldenström's Macroglobulinemia Study Involving CART-wheel): A validation of patient-reported data against the Lymphoma and Related Diseases Registry. Paper presented at Blood 2018, Brisbane, Australia.
<https://www.hsanz.org.au/resources/Documents/Blood%20Abstract%20Supplement/Blood%202018%20abstract%20supplement.pdf>